annb0t
Top 20
MELBOURNE, Australia, July 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)Â today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June 2022. All figures are in AUD$ unless otherwise stated. All figures are provided on an unaudited basis. (PRNewsfoto/Telix Pharmaceuticals Limited)
Financial Summary
Telix reports total revenue of $22.5 million from global sales of Illuccix® in its first co...
>>> Read more: Telix Reports Second Quarter 2022 Financial Results
Financial Summary
Telix reports total revenue of $22.5 million from global sales of Illuccix® in its first co...
>>> Read more: Telix Reports Second Quarter 2022 Financial Results
